TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03171402

Intervention type: DIAGNOSTIC_TEST
Intervention: Astringency and bitterness perception
Description: Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Astringency and bitterness perception
Description: Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
Study: NCT00886379

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mongolian milk without vitamin D
Description: 710ml per day for 49 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mongolian milk with vitamin D
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT milk
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Substitute
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seasonal D supplement
Description: Deliver dosage of 13,700 IU vitamin D over 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily D supplement
Description: Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
Study: NCT03515486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post stroke mood disorders evaluation
Description: Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
Study: NCT03496311

Intervention type: DIAGNOSTIC_TEST
Intervention: Acid - Base characterization
Description: Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Acid - Base characterization
Description: Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
Study: NCT00914849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukopheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Study: NCT00441909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-781
Description: 0.1% UC-781 Vaginal Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-781
Description: 0.1% UC-781 Vaginal Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-781
Description: 0.1% UC-781 Vaginal Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-781
Description: 0.1% UC-781 Vaginal Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UC-781 placebo
Description: Vaginal Gel Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UC-781 placebo
Description: Vaginal Gel Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UC-781 placebo
Description: Vaginal Gel Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UC-781 placebo
Description: Vaginal Gel Placebo
Study: NCT01312857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization to No Panitumumab
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles
Study: NCT02328924

Intervention type: OTHER
Group type: OTHER
Intervention: LH value
Description: analyzed LH value in the the arms of the study, fixed and flexible protocols

Intervention type: OTHER
Group type: OTHER
Intervention: LH value
Description: analyzed LH value in the the arms of the study, fixed and flexible protocols
Study: NCT01152255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6186
Description: Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6186
Description: Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6186
Description: Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6186
Description: Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets taken orally for seven day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets taken orally for seven day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets taken orally for seven day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets taken orally for seven day
Study: NCT01995708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
Description: Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: No vaccines
Study: NCT00770263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT02534454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation (TDCS)
Study: NCT00770263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study: NCT01553084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
Study: NCT02534454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (Habitrol)
Description: Administration of Nicotine Replacement Therapy Patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (Habitrol)
Description: Administration of Nicotine Replacement Therapy Patches
Study: NCT01553084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
Study: NCT04227899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esprit BTK Device
Description: Participants will receive Esprit BTK Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) Device
Description: Participants will receive PTA treatment
Study: NCT04021719

Intervention type: OTHER
Intervention: Stakeholder feedback
Description: Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups

Intervention type: OTHER
Intervention: Data infrastructure
Description: Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
Study: NCT03119259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABC Clinical Program
Description: The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC Clinical Program
Description: The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCN
Description: BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others.
Study: NCT02241824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-elastic lumbar brace
Study: NCT02241824

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic abdominal binder
Study: NCT04868786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
Study: NCT02415608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given orally in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given orally in 28-day cycles
Study: NCT00635206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPap auto with Fi Flex
Description: * MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP
Description: CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)
Study: NCT03985839

Intervention type: DEVICE
Intervention: MICRORAPTOR™ REGENESORB™ Suture Anchor
Description: Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.

Intervention type: DEVICE
Intervention: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Description: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.

Intervention type: DEVICE
Intervention: MICRORAPTOR™ Knotless PEEK Suture Anchor
Description: The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
Study: NCT01490151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTR controller (Medtronic)
Description: Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
Study: NCT00412984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: Oral tablets, 5.0 mg or 2.5 mg, twice daily
Study: NCT04293575

Intervention type: DEVICE
Intervention: MitraClip
Description: transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)

Intervention type: DEVICE
Intervention: MitraClip
Description: transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)

Intervention type: DEVICE
Intervention: MitraClip
Description: transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
Study: NCT02854345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomoscintigraphic parathyroid imaging on a CZT camera
Study: NCT03160118

Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal,quadrivalent,influenza vaccine
Description: 1 dose to be administered on Day 0, the first visit
Study: NCT00107198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo IFRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01341834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 and RAD001
Description: Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
Study: NCT03613532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Part 1: 6-7 total doses depending on dose level assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given once daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given twice daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Part 2 and Part 3: 14 doses for 8-12 cycles depending on dose level assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Part 2: 5 doses for 8-12 cycles depending on dose level assigned
Study: NCT02610127

Intervention type: BIOLOGICAL
Intervention: OBIZUR
Description: Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.

Intervention type: BIOLOGICAL
Intervention: OBIZUR
Description: Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
Study: NCT00848926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous infusion
Study: NCT03613532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine/cedazuridine
Description: Part 3: 3 doses for 8 cycles
Study: NCT02698215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 1 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline plus Naltrexone
Description: Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
Study: NCT03293641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate Tablets
Description: Zinc Sulfate Tablets 3 times every 7 days for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
Study: NCT03656237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Training
Description: Training in a classroom setting of health care providers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Training
Description: Training in a classroom setting of health care providers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits + LDHF Training
Description: Clinical audits followed by case-based low-dose high-frequency training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits + LDHF Training
Description: Clinical audits followed by case-based low-dose high-frequency training
Study: NCT01485081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Danubio paclitaxel-eluting balloon
Description: Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
Study: NCT02684851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid: anti-fibrinolytic agents